Combined Strategies for Nanodrugs Noninvasively Overcoming the Blood–Brain Barrier and Actively Targeting Glioma Lesions
Source abstract
Abstract
Drugs for tumor treatment face various challenges, including poor solubility, poor stability, short blood half-life, nontargeting ability, and strong toxic side effects. Fortunately, nanodrug delivery systems provide excellent solution to these problems. However, nanodrugs for glioma treatment also face some key challenges including overcoming the blood–brain barrier (BBB) and, specifically, accumulation in glioma lesions. In this review, we systematically summarize the advantages and disadvantages of combined strategies for nanodrugs noninvasively overcoming BBB and actively targeting glioma lesions to achieve effective glioma therapy. Common noninvasive strategies for nanodrugs overcoming the BBB include bypassing the BBB via the nose-to-brain route, opening the tight junction of the BBB by focused ultrasound with microbubbles, and transendothelial cell transport by intact cell loading, ligand decoration, or cell membrane camouflage of nanodrugs. Actively targeting glioma lesions after overcoming the BBB is another key factor helping nanodrugs accurately treat in situ gliomas. This aim can also be achieved by loading nanodrugs into intact cells and modifying ligand or cell membrane fragments on the surface of nanodrugs. Targeting decorated nanodrugs can guarantee precise glioma killing and avoid side effects on normal brain tissues that contribute to the specific recognition of glioma lesions. Furthermore, the challenges and prospects of nanodrugs in clinical glioma treatment are discussed.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Graphene and Nanomaterials Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
College of Basic Medicine and Forensic Medicine, Henan University of Science and Technology, Luoyang, Henan Province 471000, China.
Henan Key Laboratory of Brain Targeted Bio-nanomedicine, School of Life Sciences, Henan University, Kaifeng, Henan Province 475004, China.
Funding
National Key Research and Development Program of China · Henan Provincial Science and Technology Research Project
References (100+)
Show source-provided references
1. Barnholtz-Sloan JS , Ostrom QT , Cote D . Epidemiology of brain tumors. Neurol Clin. 2018;36(3):395–419.10.1016/j.ncl.2018.04.001 ↗
2. 10.1007/s00401-007-0243-410.1007/s00401-007-0243-4 ↗
3. El Atat O , Naser R , Abdelkhalek M , Habib RA , El Sibai M . Molecular targeted therapy: A new avenue in glioblastoma treatment. Oncol Lett. 2023;25(2):1–33.
4. 10.1007/s00401-015-1432-110.1007/s00401-015-1432-1 ↗
5. 10.1056/NEJMra070812610.1056/NEJMra0708126 ↗
6. Hanif F , Muzaffar K , Perveen K , Malhi SM , Simjee SU . Glioblastoma multiforme: A review of its epidemiology and pathogenesis through clinical presentation and treatment. Asian Pac J Cancer Prev. 2017;18(1):3–9.
7. Toader C , Eva L , Costea D , Corlatescu AD , Covache-Busuioc RA , Bratu BG , Glavan LA , Costin HP , Popa AA , Ciurea AV . Low-grade gliomas: Histological subtypes, molecular mechanisms, and treatment strategies. Brain Sci. 2023;13(12):1700.10.3390/brainsci13121700 ↗
8. McKinnon C , Nandhabalan M , Murray SA , Plaha P . Glioblastoma: Clinical presentation, diagnosis, and management. BMJ. 2021;374:Article n1560.10.1136/bmj.n1560 ↗
9. 10.3389/fonc.2018.0062410.3389/fonc.2018.00624 ↗
10. Bellotti E , Schilling AL , Little SR , Decuzzi P . Injectable thermoresponsive hydrogels as drug delivery system for the treatment of central nervous system disorders: A review. J Control Release. 2021;329:16–35.10.1016/j.jconrel.2020.11.049 ↗
11. 10.1016/j.drudis.2006.10.01310.1016/j.drudis.2006.10.013 ↗
12. Li J , Zhao J , Tan T , Liu M , Zeng Z , Zeng Y , Zhang L , Fu C , Chen D , Xie T . Nanoparticle drug delivery system for glioma and its efficacy improvement strategies: A comprehensive review. Int J Nanomedicine. 2020;15:2563–2582.10.2147/IJN.S243223 ↗
13. Akhter MH , Rizwanullah M , Ahmad J , Amin S , Ahmad MZ , Minhaj MA , Mujtaba MA , Ali J . Molecular targets and nanoparticulate systems designed for the improved therapeutic intervention in glioblastoma multiforme. Drug Res. 2021;71(3):122–137.10.1055/a-1296-7870 ↗
14. Marchetti L , Engelhardt B . Immune cell trafficking across the blood-brain barrier in the absence and presence of neuroinflammation. Vasc Biol. 2020;2(1):H1–H18.10.1530/VB-19-0033 ↗
15. 10.3390/pharmaceutics1301001510.3390/pharmaceutics13010015 ↗
16. 10.3390/molecules2423431210.3390/molecules24234312 ↗
17. Van Woensel M , Wauthoz N , Rosière R , Amighi K , Mathieu V , Lefranc F , Van Gool SW , De Vleeschouwer S . Formulations for intranasal delivery of pharmacological agents to combat brain disease: A new opportunity to tackle GBM? Cancers. 2013;5(3):1020–1048.10.3390/cancers5031020 ↗
18. Sandbhor P , Goda J , Mohanty B , Gera P , Yadav S , Chekuri G , Chaudhari P , Dutt S , Banerjee R . Targeted nano-delivery of chemotherapy via intranasal route suppresses in vivo glioblastoma growth and prolongs survival in the intracranial mouse model. Drug Delivery Transl Res. 2023;13(2):608–626.10.1007/s13346-022-01220-8 ↗
19. Chu L , Wang A , Ni L , Yan X , Song Y , Zhao M , Sun K , Mu H , Liu S , Wu Z , et al. Nose-to-brain delivery of temozolomide-loaded PLGA nanoparticles functionalized with anti-EPHA3 for glioblastoma targeting. Drug Deliv. 2018;25(1):1634–1641.10.1080/10717544.2018.1494226 ↗
20. Kanazawa T , Taki H , Okada H . Nose-to-brain drug delivery system with ligand/cell-penetrating peptide-modified polymeric nano-micelles for intracerebral gliomas. Eur J Pharm Biopharm. 2020;152:85–94.10.1016/j.ejpb.2020.05.001 ↗
21. Nwafor DC , Obiri-Yeboah D , Fazad F , Blanks W , Mut M . Focused ultrasound as a treatment modality for gliomas. Front Neurol. 2024;15:1387986.10.3389/fneur.2024.1387986 ↗
22. 10.3390/cancers1310239110.3390/cancers13102391 ↗
23. 10.1007/s00018-021-03904-910.1007/s00018-021-03904-9 ↗
24. Fateh ST , Moradi L , Kohan E , Hamblin MR , Dezfuli AS . Comprehensive review on ultrasound-responsive theranostic nanomaterials: Mechanisms, structures and medical applications. Beilstein J Nanotechnol. 2021;12(1):808–862.10.3762/bjnano.12.64 ↗
25. 10.1007/s13311-017-0515-110.1007/s13311-017-0515-1 ↗
26. Cai Q , Li X , Xiong H , Fan H , Gao X , Vemireddy V , Margolis R , Li J , Ge X , Giannotta M , et al. Optical blood-brain-tumor barrier modulation expands therapeutic options for glioblastoma treatment. Nat Commun. 2023;14(1):4934.10.1038/s41467-023-40579-1 ↗
27. 10.1021/acsanm.0c0229710.1021/acsanm.0c02297 ↗
28. Wu JR , Hernandez Y , Miyasaki KF , Kwon EJ . Engineered nanomaterials that exploit blood-brain barrier dysfunction for delivery to the brain. Adv Drug Del Rev. 2023;197: Article 114820.10.1016/j.addr.2023.114820 ↗
29. McMahon D , Hynynen K . Acute inflammatory response following increased blood-brain barrier permeability induced by focused ultrasound is dependent on microbubble dose. Theranostics. 2017;7(16):3989–4000.10.7150/thno.21630 ↗
30. 10.1016/j.canlet.2018.01.03510.1016/j.canlet.2018.01.035 ↗
31. Yang Q , Zhou Y , Chen J , Huang N , Wang Z , Cheng Y . Gene therapy for drug-resistant glioblastoma via lipid-polymer hybrid nanoparticles combined with focused ultrasound. Int J Nanomedicine. 2021;16:185–199.10.2147/IJN.S286221 ↗
32. 10.1016/j.jconrel.2012.02.02310.1016/j.jconrel.2012.02.023 ↗
33. 10.3390/polym1404071210.3390/polym14040712 ↗
34. Wang S , Meng Y , Li C , Qian M , Huang R . Receptor-mediated drug delivery systems targeting to glioma. Nanomaterials. 2015;6(1):3.10.3390/nano6010003 ↗
35. Hosseinalizadeh H , Mahmoodpour M , Bahabadi ZR , Hamblin MR , Mirzaei H . Neutrophil mediated drug delivery for targeted glioblastoma therapy: A comprehensive review. Biomed Pharmacother. 2022;156:Article 113841.10.1016/j.biopha.2022.113841 ↗
36. 10.1038/nnano.2017.5410.1038/nnano.2017.54 ↗
37. Yang L , Zhang K , Zheng D , Bai Y , Yue D , Wu L , Ling H , Ni S , Zou H , Ye B , et al. Platelet-based nanoparticles with stimuli-responsive for anti-tumor therapy. Int J Nanomedicine. 2023;18:6293–6309.10.2147/IJN.S436373 ↗
38. Lin YJ , Wei KC , Chen PY , Lim M , Hwang TL . Roles of neutrophils in glioma and brain metastases. Front Immunol. 2021;12:Article 701383.10.3389/fimmu.2021.701383 ↗
39. Ding M , Zhu A , Zhang Y , Liu J , Lin L , Wang X , Li J . Neutrophil-based Trojan horse containing polymer nano-therapeutics for sono-activatable ferroptosis-immunotherapy of orthotopic glioma. Nano Today. 2024;57:Article 102398.10.1016/j.nantod.2024.102398 ↗
40. Peng Y , Chen F , Li S , Liu X , Wang C , Yu C , Li W . Tumor-associated macrophages as treatment targets in glioma. Brain Sci Adv. 2021;6:306–323.10.26599/BSA.2020.9050015 ↗
41. 10.1021/acsami.1c1240610.1021/acsami.1c12406 ↗
42. Ibarra LE , Beaugé L , Arias-Ramos N , Rivarola VA , Chesta CA , López-Larrubia P , Palacios RE . Trojan horse monocyte-mediated delivery of conjugated polymer nanoparticles for improved photodynamic therapy of glioblastoma. Nanomedicine. 2020;15(17):1687–1707.10.2217/nnm-2020-0106 ↗
43. 10.1002/cam4.551110.1002/cam4.5511 ↗
44. Li T-F , Li K , Zhang Q , Wang C , Yue Y , Chen Z , Yuan S-J , Liu X , Wen Y , Han M , et al. Dendritic cell-mediated delivery of doxorubicin-polyglycerol-nanodiamond composites elicits enhanced anti-cancer immune response in glioblastoma. Biomaterials. 2018;181:35–52.10.1016/j.biomaterials.2018.07.035 ↗
45. Jiang Z , Zhang H , Zhang W , Zhang Y , Cui Y , Mei L , Wang Q . Smart platelet-based biohybrid delivery system for magnetic-guided targeted delivery and enhanced photothermal-chemo therapy against glioma. Nano Today. 2024;56:Article 102295.10.1016/j.nantod.2024.102295 ↗
46. Zhang D , Tian S , Liu Y , Zheng M , Yang X , Zou Y , Shi B , Luo L . Near infrared-activatable biomimetic nanogels enabling deep tumor drug penetration inhibit orthotopic glioblastoma. Nat Commun. 2022;13(1):6835.10.1038/s41467-022-34462-8 ↗
47. Su J , Yao Z , Chen Z , Zhou S , Wang Z , Xia H , Liu S , Wu Y . TfR aptamer enhanced blood-brain barrier penetration of biomimetic nanocomplexes for intracellular transglutaminase 2 imaging and silencing in glioma. Small. 2022;18(40):2203448.10.1002/smll.202203448 ↗
48. 10.1021/acs.bioconjchem.2c0038910.1021/acs.bioconjchem.2c00389 ↗
49. 10.1016/j.addr.2021.01.01210.1016/j.addr.2021.01.012 ↗
50. McCord E , Pawar S , Koneru T , Tatiparti K , Sau S , Iyer AK . Folate receptors’ expression in gliomas may possess potential nanoparticle-based drug delivery opportunities. ACS Omega. 2021;6(6):4111–4118.10.1021/acsomega.0c05500 ↗
51. Anthony DP , Hegde M , Shetty SS , Rafic T , Mutalik S , Rao BS . Targeting receptor-ligand chemistry for drug delivery across blood-brain barrier in brain diseases. Life Sci. 2021;274:Article 119326.10.1016/j.lfs.2021.119326 ↗
52. Li J , Du Y , Jiang Z , Tian Y , Qiu N , Wang Y , Hu M , Zou R , Luo L , Du S . Y1 receptor ligand-based nanomicelle as a novel nanoprobe for glioma-targeted imaging and therapy. Nanoscale. 2018;10(13):5845–5851.10.1039/C8NR00148K ↗
53. Farshbaf M , Mojarad-Jabali S , Hemmati S , Khosroushahi AY , Motasadizadeh H , Zarebkohan A , Valizadeh H . Enhanced BBB and BBTB penetration and improved anti-glioma behavior of bortezomib through dual-targeting nanostructured lipid carriers. J Control Release. 2022;345:371–384.10.1016/j.jconrel.2022.03.019 ↗
54. Shi W , Cui X , Shi J , Chen J , Wang Y . Overcoming the blood-brain barrier for glioma-targeted therapy based on an interleukin-6 receptor-mediated micelle system. RSC Adv. 2017;7(44):27162–27169.10.1039/C7RA03208K ↗
55. 10.1124/mol.107.03885110.1124/mol.107.038851 ↗
56. Roberts L , Black D , Raman C , Woodford K , Zhou M , Haggerty J , Yan A , Cwirla S , Grindstaff K . Subcellular localization of transporters along the rat blood-brain barrier and blood-cerebral-spinal fluid barrier by in vivo biotinylation. Neuroscience. 2008;155(2):423–438.10.1016/j.neuroscience.2008.06.015 ↗
57. Zhang Y , Cheng Q , Xue Y , Yao K , Syeda MZ , Xu J , Wu J , Wang Z , Tang L , Mu Q . LAT1 targeted brain delivery of temozolomide and sorafenib for effective glioma therapy. Nano Res. 2023;16:9743–9751.10.1007/s12274-023-5568-3 ↗
58. Wu X , Prasad PD , Leibach FH , Ganapathy V . cDNA sequence, transport function, and genomic organization of human OCTN2, a new member of the organic cation transporter family. Biochem Biophys Res Commun. 1998;246(3):589–595.10.1006/bbrc.1998.8669 ↗
59. Kou L , Hou Y , Yao Q , Guo W , Wang G , Wang M , Fu Q , He Z , Ganapathy V , Sun J . L-carnitine-conjugated nanoparticles to promote permeation across blood-brain barrier and to target glioma cells for drug delivery via the novel organic cation/carnitine transporter OCTN2. Artif Cells, Nanomed Biotechnol. 2018;46(8):1605–1616.
60. Vieira DB , Gamarra LF . Getting into the brain: Liposome-based strategies for effective drug delivery across the blood-brain barrier. Int J Nanomedicine. 2016;11:5381–5414.10.2147/IJN.S117210 ↗
61. 10.1002/cyto.a.2271510.1002/cyto.a.22715 ↗
62. 10.3390/pharmaceutics1402027910.3390/pharmaceutics14020279 ↗
63. Xie J , Shen Z , Anraku Y , Kataoka K , Chen X . Nanomaterial-based blood-brain-barrier (BBB) crossing strategies. Biomaterials. 2019;224:Article 119491.10.1016/j.biomaterials.2019.119491 ↗
64. Zhang B , Sun X , Mei H , Wang Y , Liao Z , Chen J , Zhang Q , Hu Y , Pang Z , Jiang X . LDLR-mediated peptide-22-conjugated nanoparticles for dual-targeting therapy of brain glioma. Biomaterials. 2013;34(36):9171–9182.10.1016/j.biomaterials.2013.08.039 ↗
65. Ye Z , Zhang T , He W , Jin H , Liu C , Yang Z , Ren J . Methotrexate-loaded extracellular vesicles functionalized with therapeutic and targeted peptides for the treatment of glioblastoma multiforme. ACS Appl Mater Interfaces. 2018;10(15):12341–12350.10.1021/acsami.7b18135 ↗
66. Pizzocri M , Re F , Stanzani E , Formicola B , Tamborini M , Lauranzano E , Ungaro F , Rodighiero S , Francolini M , Gregori M , et al. Radiation and adjuvant drug-loaded liposomes target glioblastoma stem cells and trigger in-situ immune response. Neurooncol Adv. 2021;3(1):vdab076.
67. Najafi F , Moghimi HR , Hemmati M , Deevband MR , Kazemi B . SRL-coated PAMAM dendrimer nano-carrier for targeted gene delivery to the glioma cells and competitive inhibition by lactoferrin. Iran J Pharm Res. 2016;15(4):629–640.
68. Ruan H , Chai Z , Shen Q , Chen X , Su B , Xie C , Zhan C , Yao S , Wang H , Zhang M , et al. A novel peptide ligand RAP12 of LRP1 for glioma targeted drug delivery. J Control Release. 2018;279:306–315.10.1016/j.jconrel.2018.04.035 ↗
69. Ruan H , Yao S , Wang S , Wang R , Xie C , Guo H , Lu W . Stapled RAP12 peptide ligand of LRP1 for micelles-based multifunctional glioma-targeted drug delivery. Chem Eng J. 2021;403:Article 126296.10.1016/j.cej.2020.126296 ↗
70. He W , Li X , Morsch M , Ismail M , Liu Y , Rehman FU , Zhang D , Wang Y , Zheng M , Chung R , et al. Brain-targeted codelivery of Bcl-2/Bcl-xl and Mcl-1 inhibitors by biomimetic nanoparticles for orthotopic glioblastoma therapy. ACS Nano. 2022;16(4):6293–6308.10.1021/acsnano.2c00320 ↗
71. Zheng M , Liu Y , Wang Y , Zhang D , Zou Y , Ruan W , Yin J , Tao W , Park JB , Shi B . ROS-responsive polymeric siRNA nanomedicine stabilized by triple interactions for the robust glioblastoma combinational RNAi therapy. Adv Mater. 2019;31(37):1903277.10.1002/adma.201903277 ↗
72. Liu Y , Zheng M , Jiao M , Yan C , Xu S , Du Q , Morsch M , Yin J , Shi B . Polymeric nanoparticle mediated inhibition of miR-21 with enhanced miR-124 expression for combinatorial glioblastoma therapy. Biomaterials. 2021;276:Article 121036.10.1016/j.biomaterials.2021.121036 ↗
73. 10.1021/acsnano.8b0526510.1021/acsnano.8b05265 ↗
74. Sun P , Xiao Y , Di Q , Ma W , Ma X , Wang Q , Chen W . Transferrin receptor-targeted PEG-PLA polymeric micelles for chemotherapy against glioblastoma multiforme. Int J Nanomedecine. 2020;15:6673–6688.10.2147/IJN.S257459 ↗
75. Liu X , Cao Z , Liu N , Gao G , Du M , Wang Y , Cheng B , Zhu M , Jia B , Pan L . Kill two birds with one stone: Engineered exosome-mediated delivery of cholesterol modified YY1-siRNA enhances chemoradiotherapy sensitivity of glioblastoma. Front Pharmacol. 2022;13:Article 975291.10.3389/fphar.2022.975291 ↗
76. Yue J , Liu S , Wang R , Hu X , Xie Z , Huang Y , Jing X . Fluorescence-labeled immunomicelles: Preparation, in vivo biodistribution, and ability to cross the blood-brain barrier. Macromol Biosci. 2012;12(9):1209–1219.10.1002/mabi.201200037 ↗
77. 10.1021/am402128s10.1021/am402128s ↗
78. Guo J , Schlich M , Cryan JF , O’Driscoll CM . Targeted drug delivery via folate receptors for the treatment of brain cancer: Can the promise deliver? J Pharm Sci. 2017;106(12):3413–3420.10.1016/j.xphs.2017.08.009 ↗
79. Afzalipour R , Khoei S , Khoee S , Shirvalilou S , Jamali Raoufi N , Motevalian M , Karimi MR . Dual-targeting temozolomide loaded in folate-conjugated magnetic triblock copolymer nanoparticles to improve the therapeutic efficiency of rat brain gliomas. ACS Biomater Sci Eng. 2019;5(11):6000–6011.10.1021/acsbiomaterials.9b00856 ↗
80. Wang Y , Su Y , Yang Y , Jin H , Wu M , Wang Q , Sun P , Zhang J , Yang X , Shu X . Increased brain uptake of pterostilbene loaded folate modified micellar delivery system. Drug Deliv. 2022;29(1):3071–3086.10.1080/10717544.2022.2126559 ↗
81. 10.1002/ange.20141122610.1002/ange.201411226 ↗
82. Zhang D , Kong J , Huang X , Zeng J , Du Q , Yang T , Yue H , Bao Q , Miao Y , Xu Y . Targeted glioblastoma therapy by integrating brain-targeting peptides and corn-derived cancer cell-penetrating proteins into nanoparticles to cross blood-brain tumor barriers. Mater Today Nano. 2023;23:Article 100347.10.1016/j.mtnano.2023.100347 ↗
83. Jiang X , Xin H , Ren Q , Gu J , Zhu L , Du F , Feng C , Xie Y , Sha X , Fang X . Nanoparticles of 2-deoxy-D-glucose functionalized poly(ethylene glycol)-co-poly(trimethylene carbonate) for dual-targeted drug delivery in glioma treatment. Biomaterials. 2014;35(1):518–529.10.1016/j.biomaterials.2013.09.094 ↗
84. Wang S , An J , Dong W , Wang X , Sheng J , Jia Y , He Y , Ma X , Wang J , Yu D , et al. Glucose-coated berberine nanodrug for glioma therapy through mitochondrial pathway. Int J Nanomed. 2020;15:7951–7965.10.2147/IJN.S213079 ↗
85. Li L , Di X , Zhang S , Kan Q , Liu H , Lu T , Wang Y , Fu Q , Sun J , He Z . Large amino acid transporter 1 mediated glutamate modified docetaxel-loaded liposomes for glioma targeting. Colloids Surf B Biointerfaces. 2016;141:260–267.10.1016/j.colsurfb.2016.01.041 ↗
86. 10.1002/adma.20170675910.1002/adma.201706759 ↗
87. 10.1016/j.apsb.2017.11.00910.1016/j.apsb.2017.11.009 ↗
88. Li H , Li S , Lin Y , Chen S , Yang L , Huang X , Wang H , Yu X , Zhang L . Artificial exosomes mediated spatiotemporal-resolved and targeted delivery of epigenetic inhibitors. J Nanobiotechnol. 2021;19(1):364.10.1186/s12951-021-01107-9 ↗
89. Wan X , Song L , Pan W , Zhong H , Li N , Tang B . Tumor-targeted cascade nanoreactor based on metal-organic frameworks for synergistic ferroptosis-starvation anticancer therapy. ACS Nano. 2020;14(9):11017–11028.10.1021/acsnano.9b07789 ↗
90. Zhao Y-Z , Shen B-X , Li X-Z , Tong M-Q , Xue P-P , Chen R , Yao Q , Chen B , Xiao J , Xu H-L . Tumor cellular membrane camouflaged liposomes as a non-invasive vehicle for genes: Specific targeting toward homologous gliomas and traversing the blood-brain barrier. Nanoscale. 2020;12(28):15473–15494.10.1039/D0NR04212A ↗
91. 10.1021/acsnano.6b0469510.1021/acsnano.6b04695 ↗
92. Zou Y , Wang Y , Xu S , Liu Y , Yin J , Lovejoy DB , Zheng M , Liang XJ , Park JB , Efremov YM , et al. Brain co-delivery of temozolomide and cisplatin for combinatorial glioblastoma chemotherapy. Adv Mater. 2022;34(33):2203958.10.1002/adma.202203958 ↗
93. Zhang H , Guan S , Wei T , Wang T , Zhang J , You Y , Wang Z , Dai Z . Homotypic membrane-enhanced blood-brain barrier crossing and glioblastoma targeting for precise surgical resection and photothermal therapy. J Am Chem Soc. 2023;145(10):5930–5940.10.1021/jacs.2c13701 ↗
94. 10.1016/j.bioactmat.2022.11.01610.1016/j.bioactmat.2022.11.016 ↗
95. Bi Y , Qian P , Su Z , Dai W , Xu F , Luo C . Construction of biomimetic camouflaged neutrophil membrane nanoparticles for precise delivery and augmented glioma cancer treatment. Process Biochem. 2024;145:229–242.10.1016/j.procbio.2024.06.021 ↗
96. 10.1038/s41582-018-0025-810.1038/s41582-018-0025-8 ↗
97. Yin Y , Tang W , Ma X , Tang L , Zhang Y , Yang M , Hu F , Li G , Wang Y . Biomimetic neutrophil and macrophage dual membrane-coated nanoplatform with orchestrated tumor-microenvironment responsive capability promotes therapeutic efficacy against glioma. Chem Eng J. 2022;433:Article 133848.10.1016/j.cej.2021.133848 ↗
98. Dobbie MS , Hurst RD , Klein NJ , Surtees RA . Upregulation of intercellular adhesion molecule-1 expression on human endothelial cells by tumour necrosis factor-α in an in vitro model of the blood-brain barrier. Brain Res. 1999;830(2): 330–336.10.1016/S0006-8993(99)01436-5 ↗
99. Cheng VW , de Pennington N , Zakaria R , Larkin JR , Serres S , Sarkar M , Kirkman MA , Bristow C , Croal P , Plaha P , et al. VCAM-1-targeted MRI improves detection of the tumor-brain interface. Clin Cancer Res. 2022;28(11):2385–2396.10.1158/1078-0432.CCR-21-4011 ↗
100. Mäenpää A , Kovanen PE , Anders P , Juha J , Tuomo T . Lymphocyte adhesion molecule ligands and extracellular matrix proteins in gliomas and normal brain: Expression of VCAM-1 in gliomas. Acta Neuropathol. 1997;94(3):216–225.10.1007/s004010050696 ↗